New therapies for hepatitis C;Nuevos tratamientos para la hepatitis C

Medicina Clinica

Volumn 127, Issue 3, 2006, Pages 104-112

  Gil Guerrero, Lucía ^a   Sarobe, Pablo ^a   Prieto, Jesús ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN ALPHA INTERFERON; ALPHA INTERFERON; AMANTADINE; ANA 975; ANTIVIRUS AGENT; CASTANOSPERMINE 6 BUTYRATE; CICAVIR; CONSENSUS INTERFERON; CPG 10101; CYTOKINE; GAMMA INTERFERON; HISTAMINE; IC 41; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT; ISATORIBINE; JTK 003; NEUTRALIZING ANTIBODY; NUCLEOSIDE ANALOG; PEGINTERFERON; PROTEINASE; RIBAVIRIN; SILYMARIN; THYMOSIN ALPHA1; UNCLASSIFIED DRUG; VACCINE; VALOPICITABINE; VIRUS PROTEIN; VX 950; XLT 6865;

ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOMODULATION; IMMUNOSTIMULATION; INFECTION CONTROL; PREVALENCE; PROTEIN FUNCTION; PROTEIN STRUCTURE; PUBLIC HEALTH; REVIEW; TREATMENT RESPONSE; VACCINATION; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 33746383042     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13090267     Document Type: Review

References (52)

1. Romero-Gómez M, Vitoria MM, Andrade RJ, Salmeron J, Diago M, Fernández-Rodríguez, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636-41
2. Galeras JA, Cirera I, Coll S, Jiménez MD, Marquez C, Bory F, et al. Long-term follow-up of chronic hepatitis C patients non-responders to antiviral treatment. Hepatology. 2003;38:442A.
3. Neuman AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998;282:103-7.
4. Lau JY, Tam RC, Liang TJ, Hong Z. Mechanisms of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology. 2002;35:1002-9.
5. Crotty S, Cameron CE, Andino R. The broad spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat Med. 2000;6:1375-9.
6. Pestka S. The human interferon alpha species and receptors. Biopolymers. 2000;55:254-87.
7. Pfeffer LM, Basu L, Pfeffer SR, Yang CH, Murti A, Russell-Harde D, et al. The short form of the interferon alpha/beta receptor chain 2 acts as a dominant negative for type I interferon action. J Biol Chem. 1997;272:11002-5.
8. David M. Signal transduction by type I interferons. Biotechniques 2002 [Suppl],33:58-65.
9. Yang CH, Murti A, Pfeffer LM. STAT3 complements defects in an interferon-resistant cell line: evidence for an essential rale for STAT3 in interferon signaling and biological activities. Proc Natl Acad Sci U S A. 1998;95:5568-72.
10. Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem. 1998;67:227-64.
11. Castelruiz Y, Larrea E, Boya P, Civeira MP, Prieto J. Interferon alfa subtypes and levels of type I interferons in the liver and peripheral mononuclear cells in patients with chronic hepatitis C and controls. Hepatology. 1999;29:1900-4.
12. Foy E, Li K, Wang C, Sumpter R Jr, Ikeda M, Lemon SM, et al. Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. Science. 2003;300:1145-8.
13. Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. Science. 1999;285:107-10.
14. Gale MJ, Korth MJ, Katze MG. Repression of the PKR protein kinase by hepatitis C virus NS5A protein: a potential mechanism of interferon resistance. Clin Diag Virol. 1998;10:157-62.
15. Larrea E, Aldabe R, Molano E, Fernández-Rodríguez CM, Ametzazurra A, Civeira MP, et al. Altered expression and activation of STATs (signal transduction and activator of transcription) in HCV infection: in vivo and in vitro studies. Gut 2005. Disponible en: http://gut.bmjjournals.com/cgi/ content/abstract/gut.2005.070060vl
16. Masci P, Bukowski RM, Patten PA, Osborn BL, Borden EC. New and modified interferon alphas: preclinical and clinical data. Curr Oncol Rep. 2003;5:108-13.
17. Pockros PJ. Developments in the treatment of chronic hepatitis C. Expert Opin Invest Drugs. 2002;11:515-28.
18. Pawlotsky JM. Current and future concepts in hepatitis C therapy. Sem Liver Dis. 2005;25:72-83.
19. Moskovitz DN, Manoharan P, Heathcote EJ. High dose consensus interferon in nonresponders to interferon alpha-2b and ribavirin with chronic hepatitis C. Can J Gastroenterol. 2003;17:479-82.
20. Pawlotsky JM, McHutchison JG. Hepatitis C. Developement of new drugs and clinical trials: promises and pitfalls. Summary of an AASLD hepatitis single topic conference. Hepatology. 2004;39:554-67.
21. Leevy C, Blatt LM, Chalmers C. Interim results of a pilot study of the combination of type 1 (IFN alfacon 1) and type 2 (IFN gamma 1b) interferons in chronic hepatitis C patients who have failed to respond to peginterferon alfa-2a plus ribavirin. Hepatology. 2004;40 Suppl 1:394A.
22. Larrea E, Aldabe R, Riezu-Boj JI, Guitart A, Civeira MP, Prieto J, et al. IFN-alpha5 mediates stronger Tyk2-stat-dependent activation and higher expression of 2′,5′-oligoadenylate synthetase than IFN-alpha2 in liver cells. J Interferon Cytokine Res. 2004;24:497-503.
23. Lasarte JJ, García-Granero M, López A, Casares N, García N, Civeira MP, et al. Cellular immunity to hepatitis C virus core protein and the response to interferon in patients with chronic hepatitis C. Hepatology. 1998;28:815-22.
24. Sarobe P, Jauregui JI, Lasarte JJ, García N, Civeira MP, Borrás-Cuesta F, et al. Production of interleukin-2 in response to synthetic peptides from hepatitis C virus E1 protein in patients with chronic hepatitis C: relationship with the response to interferon treatment. J Hepatol. 1996;25:1-9.
25. Sarobe P, Lasarte JJ, Zabaleta A, Arribillaga L, Arina A, Melero I, et al. Hepatitis C virus structural proteins impair dendritic cell maturation and inhibit in vivo induction of cellular immune responses. J Virol. 2003;77:10862-71.
26. Beutler B. Inferences, questions and possibilities in toll-like receptor signaling. Nature. 2004;430:257-71.
27. Bowie AG, Haga IR. The role of Toll-like receptors in the host response to viruses. Mol Immunol. 200;42:859-67.
28. Akira S, Takeda K. Toll-like receptor signaling. Nature. 2004;4:499-511.
29. Li K, Foy E, Ferreon J, Nakamura M, Ferreon A, Ikeda M, et al. Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the toll-like receptors adaptor protein TRIF. Proc Natl Acad Sci U S A. 2005;102:2992-7.
30. Horsmans Y, Berg T, Desager JP, Mueller T, Schott E, Fletcher SP, et al. Isatoribine, an agonist of TLR7, reduces plasma virus concentration in chronic hepatitis C infection. Hepatology. 2005;42:724-31.
31. Bayes M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2005;27:193-219.
32. Lurie Y, Nevens F, Aprosina ZG, Fedorova TA, Kalinin AV, Klimova EA, et al. A multicenter randomized study to evaluate the safety and efficacy of histamine dihydrochloride and interferon alpha-2b for the treatment of chronic hepatitis C. J Viral Hepatol. 2002;9:346-353.
33. Andreone P, Gramenzi A, Cursaro C, Felline F, Loggi E, Derrico A, et al. Thymosin-alpha 1 plus interferon-alpha for anive patients with chronic hepatitis C: results of a randomized controlled pilot trial. J Viral Hepat. 2004;11:69-73.
34. Brillanti S, Levantesi F, Masi L, Foli M, Bolondi L. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C. Hepatology. 2000;32:630-4.
35. Sarobe P, Lasarte JJ, Casares N, López-Díaz de Cerio A, Baixeras E, Labarga P, et al. Abnormal priming of CD4(+) T cells by dendritic cells expressing hepatitis C virus core and E1 proteins. J Virol. 2002;76:5062-70.
36. rd annual scientific Meeting of the Australasian Society of Immunology (ASI); Perth 2003 dec 7-11.
37. Manns MP, Berg, Wedemeyer H, Hinrichsen H. Immunization with the therapeutic hepatitis C virus (HCV) peptide vaccine IC41 in 66 chronic hepatitis C non responder patients [resumen 195]. Actas del 55 Annual Meeting of American Association for the Study of Liver Disease; 2004, octubre 29-noviembre 2; Boston. Boston: American Association for the Study of Liver Disease; 2004.
38. Nevens F, Roskams T, Van Vlierberghe H, Horsmans Y, Sprengers D, Elewaut A, et al. A pilot study of therapeutic vaccination with envelope protein El in 35 patients with chronic hepatitis C. Hepatology. 2003;38:1289-96.
39. Arribillaga L, De Cerio AL, Sarobe P, Casares N, Gorraiz M, Vales A, et al. Vaccination with an adenoviral vector encoding hepatitis C virus (HCV) NS3 protein protects against infection with HCV-recombinant vaccinia virus. Vaccine. 2002;21:202-10.
40. Arribillaga L, Sarobe P, Arina A, Gorraiz M, Borras-Cuesta F, Ruiz J, et al. Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus. Vaccine. 2005;23:3493-9.
41. Bhopale GM, Nanda RK. Emerging drugs for chronic hepatitis C. Hepatology Research. 2005;32:146-53.
42. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature. 2003;426:186-9.
43. Afdhal N, Godofsky E, Rustgi V, McEniry D, Zhou XJ. Final phase I/II trials results for NM283, a new polymerase inhibitor for hepatitis C. Antiviral efficacy and tolerance in patients with HCV 1 infection, including previous interferon failures. Disponible en: http://www.idenix.com/products/ datafiles_nm283/AfdhalAASLD04_10-04.pdf
44. Dugourd D, Fenn J, Siu R, Coulson R, Clement JJ. Synergistic inhibition of flaviviridae virus by celgosivir in combination with ribavirin or IFN-alpha. Disponible en: http://www.migenix.com/annuals/ICAR-2005_1.pdf
45. Dugourd D, Fenn J, Siu R, Coulson R, Clement JJ. In vitro characterization of celgosivir, a clinical stage compound for the treatment of HCV infections. Disponible en: http://www.migenix.com/annuals/ICAR-2005_1.pdf
46. Standring DN. NM 283 has potent antiviral activity against chronic hepatitis C virus, genotype 1, in chimpanzee. Disponible en: http://www.idenix.com/products/datafiles_nm283/StandringqEASL2004_7-03.pdf
47. Wang L, Hernández-Alcoceba R, Shankar V, Zabala M, Kochanek S, Sangro B, et al. Prolonged and inducible transgene expression in the liver using gutless adenovirus: a potential therapy for liver cancer. Gastroenterology. 2004;126:278-89.
48. Fiedler M, Rodicker F, Salucci V, Lu M, Aurisicchio L, Dahmen U, et al. Helper-dependent adenoviral vector-mediated delivery of woodchuck-specific genes for alpha interferon (IFN-alpha) and IFN-gamma: IFN-alpha but not IFN-gamma reduces woodchuck hepatitis virus replication in chronic infection in vivo. J Virol. 2004;78:10111-21.
49. Berraondo P, Ochoa L, Crettaz J, Rotellar F, Vales A, Martinez-Anso E, et al. IFN-alpha gene therapy for woodchuck hepatitis with adeno-associated virus: differences in duration of gene expression and antiviral activity using intraportal or intramuscular routes. Mol Ther. 2005;12:68-76.
50. García-Navarro R, Blanco-Urgoiti B, Berraondo P, Sánchez de la Rosa R, Vales A, Hervas-Stubbs S, et al. Protection against woodchuck hepatitis virus (WHV) infection by gene gun coimmunization with WHV core and interleukin-12. J Virol. 2001;75:9068-76.
51. Borgia G. HepeX-C (XTL biopharmaceuticals). Curr Opin Investig Drugs. 2004;5:892-7.
52. Flora K, Hahn M, Rosen H, Benner K. Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol. 1998;93:139-43.